Ferric derisomaltose

Generic Name: Ferric derisomaltose

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₃₄FeO_₁₆

CAS Number: 1345510-43-1

Unique Ingredient Identifier: AHU547PI9H

Background: Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells. Though it is generally considered non life-threatening, iron deficiency may considerably...

Indication: This drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron preparations or insufficient clinical response to orally administered iron. Ferric derisomaltase is also indicated for patients with non-hemodialysis dependent chronic kidney disease. In Australia and United Kingdom, ferric deris...

Associated Conditions: Iron Deficiency Anemia (IDA), Requirement for rapid iron delivery

Associated Therapies: -

Clinical Trials

Iron deficiency Anemia Therapeutics Market Size in the 7MM was around ...

DelveInsight's report on Iron Deficiency Anemia covers epidemiology, market trends in the US, EU4, UK, and Japan. Key trials include Dr. P. Noordzij's study on postoperative iron deficiency anemia treatment and RDC Clinical Pty Ltd's trial on IHAT. The US had 9.5 million prevalent cases in 2023, with females accounting for 65% of cases. Leading companies and therapies are highlighted, including MegaPro Biomedical's MPB-1514 and Pharmacosmos A/S's Ferric Derisomaltose. The report also discusses treatment strategies and market dynamics.

lexology.com

a month ago

A Rising EU Antitrust Enforcement Tide: 'Exclusionary Disparagement' of Pharma Rivals

The EC fined Teva €462.6 million for abusing its dominant position to delay competition to Copaxone, marking the first time a pharma company was held liable for 'exclusionary disparagement.' This decision highlights the rising tide of antitrust enforcement against disparagement practices in the pharma sector, raising questions about the boundary between legitimate competition and illegal means.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.